Darzalex 400 mg Injection

Darzalex 400 mg Injection (Daratumumab)

Darzalex 400 mg Injection contains daratumumab, a monoclonal antibody used in the treatment of multiple myeloma, a type of blood cancer affecting plasma cells. It targets and binds to the CD38 protein on the surface of multiple myeloma cells, enhancing the immune system’s ability to attack and destroy these cells.

Uses

• Treatment of Multiple Myeloma: Often used alone or in combination with other medications for patients with multiple myeloma, including newly diagnosed, relapsed, or refractory cases.
• Combination Therapy: May be administered with other agents like lenalidomide, dexamethasone, or proteasome inhibitors for enhanced treatment efficacy.

How Darzalex Works

Daratumumab binds specifically to the CD38 protein on malignant plasma cells, marking them for destruction by the immune system. It also helps modulate immune responses to reduce cancer growth and spread.

Common Side Effects

• Fatigue
• Nausea
• Cough
• Respiratory infections
• Infusion-related reactions (e.g., fever, chills, breathing difficulty)

Serious Side Effects (Seek Medical Attention)

• Severe allergic or infusion reactions
• Blood cell count abnormalities
• Liver enzyme changes
• Severe infections

Key Features

• Contains daratumumab, a targeted therapy for multiple myeloma.
• Works by binding to the CD38 protein, aiding immune-mediated destruction of cancer cells.
• Effective as part of both monotherapy and combination regimens.

Frequently Asked Questions (FAQ)

1. How is Darzalex 400 mg Injection administered?
   It is given as an intravenous infusion under the supervision of a healthcare provider, with the dose and schedule depending on treatment protocols.
2. Can Darzalex cause infusion-related reactions?
   Yes, some patients may experience reactions during or shortly after infusion. Premedication with corticosteroids, antipyretics, and antihistamines may be used to reduce this risk.
3. Is it safe for use during pregnancy?
   Darzalex is not recommended during pregnancy or breastfeeding due to potential risks to the fetus or infant. Discuss contraception options with your healthcare provider.

References

1. Darzalex (daratumumab) Information – FDA
   Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf
2. Multiple Myeloma Treatment Guidelines – NCCN
   Available from:https://pubmed.ncbi.nlm.nih.gov/37797101/